Human papillomavirus oncoproteins alter differentiation-dependent cell cycle exit on suspension in semisolid medium

Virology

Volumn 250, Issue 1, 1998, Pages 19-29

  Ruesch, Margaret N ^a   Laimins, Laimonis A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; ONCOPROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CONTROLLED STUDY; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; VIRUS CARCINOGENESIS; VIRUS PATHOGENESIS; WART VIRUS;

ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPOVAVIRIDAE;

EID: 0032505579     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9359     Document Type: Article

References (56)

1. Adams J. C., Watt F. M. Fibronectin inhibits the terminal differentiation of human keratinocytes. Nature. 340:1989;307-309.
2. Boyer S. N., Wazer D. E., Band V. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:1996;4620-4624.
3. Chen P.-L., Riley D. J., Chen Y., Lee W.-H. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev. 10:1996;2794-2804.
4. Cheng S., Schmidt-Grimminger D., Murant T., Broker T., Chow L. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9:1995;2335-2349.
5. Demers G., Espling E., Harry J., Etscheid B., Galloway D. Abrogation of growth arrest signals by human papillomavirus type 16E7 is mediated by sequences required for transformation. J. Virol. 70:1996;6862-6869.
6. Demers G., Foster S., Halbert C., Galloway D. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7 protein. Proc. Natl. Acad. Sci. USA. 91:1994;4382-4386.
7. CIP1/WAF1. Cell. 82:1995;675-684.
8. Dimri G., Nakanishsi M., Desprez P., Smith J., Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional Retinoblastoma protein. Mol. Cell. Biol. 16:1996;2987-2997.
9. Doorbar J., Foo C., Coleman N., Medcalf L., Hartley O., Prospero T., Napthine S., Sterling J., Winter G., Griffen H. Characterization of events during the late stages of HPV16 infectionin vivo. Virology. 238:1997;40-52.
10. kip1. Cell. 85:1996;733-744.
11. Foster S., Demers G., Etscheid B., Galloway D. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68:1994;5698-5705.
12. Frattini M. G., Lim H. B., Laimins L. A. In vitro. Proc. Natl. Acad. Sci. USA. 93:1996;3062-3067.
13. Funk J. O., Waga S., Harry J. B., Espling E., Stillman B., Galloway D. Inhibition of cdk activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11:1997;2090-2100.
14. Galloway D. A., McDougall J. K. The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin. Cancer Biol. 7:1996;309-315.
15. Green H. Terminal differentiation of cultured human epidermal cells. Cell. 11:1977;405-416.
16. Guo K., Walsh K. Inhibition of myogenesis by multiple cyclin-cdk complexes. J. Biol. Chem. 272:1997;791-797.
17. Halbert C., Demers G., Galloway D. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:1991;473-478.
18. Halbert C., Demers G., Galloway D. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 66:1992;2125-2134.
19. Halevy O., Novitch B. G., Spicer D. B., Skapek S. X., Rhee J., Hannon G. J., Beach D., Lassar A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science. 267:1995;1018-1021.
20. Harper J. W. Cyclin dependent kinase inhibitors. Cancer Surveys. 29:1997;91-107.
21. Kip1in vitro. Cell Growth Diff. 8:1997;203-211.
22. Hickman E., Picksley S., Vousden K. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene. 9:1994;2177-2181.
23. Hickman E. S., Espling E., Harry J. B., Etscheid B. G., Galloway D. A. Perturbation of the p53 response by human papillomavirus type 16 E7. J. Virol. 70:1997;6862-6869.
24. Howley P. M. Papillomavirinae and their replication. Fundamental Virology. 1996;Lippincott-Raven Publishers, Philadelphia. p. 947-978.
25. cip1. Genes Dev. 11:1997;2101-2111.
26. 1. J. Virol. 71:1997;2905-2912.
27. Jones D. L., Thompson D. A., Munger K. Destabilization of the Rb tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology. 239:1997;97-107.
28. Kessis T. D., Slebos R. J., Nelson W. G., Kastan M. B., Plunkett B. S., Han S. M., Lorincz A. T., Hedrick L., Cho K. R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA. 90:1993;3988-3992.
29. kip1. Cell. 85:1996;721-732.
30. Ko L., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
31. Koff A., Cross F., Fisher A., Schumacher J., Leguellec K., Philippe M., Roberts J. Human cyclin E, a new cyclin that interacts with two members of the cdc2 gene family. Cell. 66:1991;1217-1228.
32. Laimins L. The biology of human papillomaviruses: from warts to cancer. Infect. Agents Dis. 2:1993;74-86.
33. Lane D. P. p53, guardian of the genome. Nature. 358:1992;15-16.
34. Macleod K. F., Hu Y., Jacks T. Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J. 16:1996;6178-6188.
35. Meyers C., Frattini M., Hudson J., Laimins L. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science. 257:1992;971-973.
36. Missero C., Calautti E., Eckner R., Chin J., Tsai L., Livingston D., Dotto G. Involvement of the cell-cycle inhibitor Cip1/Waf1 and the E1A-associated p300 protein in terminal differentiation. Proc. Natl. Acad. Sci. USA. 92:1995;5451-5455.
37. Morozov A., Shiyanov P., Barr E., Leiden J., Raychaudhuri P. Accumulation of human papillomavirus type 16 E7 protein bypasses G1 arrest induced by serum deprivation and by the cell cycle inhibitor p21. J. Virol. 71:1997;3451-3457.
38. Munger K., Scheffner M., Huibregtse J. M., Howley P. M. Interactions of HPV E6 and E7 Oncoproteins with tumour suppressor gene products. Cancer Surveys. 12:1992;197-217.
39. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D. Y., Nakayama K. Mice lacking p27kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 85:1996;707-720.
40. Novitch B. G., Mulligan G. J., Jacks T., Lassar A. B. Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle. J. Cell Biol. 135:1996;441-456.
41. Pan H., Griep A. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev. 8:1994;1285-1299.
42. Pan H. C., Griep A. E. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev. 9:1995;2157-2169.
43. CIP1. Science. 267:1995;1024-1027.
44. Pray T. R., Laimins L. A. Differentiation-dependent expression of E1-E4 proteins in cell lines maintaining episomes of human papillomavirus type 31b. Virology. 206:1995;679-685.
45. Riley D. J., Lee E. Y.-H. P., Lee W.-H. The retinoblastoma protein: more than a tumor suppressor. Annu. Rev. Cell Biol. 10:1994;1-29.
46. Ruesch M. N., Laimins L. A. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J. Virol. 71:1997;5570-5578.
47. Ruesch M. N., Stubenrauch F., Laimins L. A. Activation of papillomavirus late gene transcription and genome amplification upon differentiation in semisolid medium is coincident with expression of involucrin and transglutaminase but not keratin-10. J. Virol. 72:1998;5016-5024.
48. Schulze A., Mannhardt B., Zerfass-Thome K., Zwerschke W., Jansen-Durr P. Anchorage-Independent transcription of the cyclin A gene induced by the E7 oncoprotein of human papillomavirus type 16. J. Virol. 72:1998;2323-2334.
49. Slebos R., Lee M., Plunkett B., Kessis T., Williams B., Jacks T., Hedrick L., Kastan M., Cho K. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA. 91:1994;5320-5324.
50. Steinman R., Hoffman B., Iro A., Guillouf C., Lieberman D., El-Houseini M. Induction of p21 (Waf-1/Cip-1) during differentiation. Oncogene. 9:1994;3389-3396.
51. Vousden K. Interactions between papillomavirus proteins and tumor suppressor gene products. Adv. Cancer Res. 64:1994;1-24.
52. Weinberg R. The Retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
53. Kip2. Genes Dev. 11:1997;973-983.
54. Zacksenhaus E., Jiang Z., Chung D., Marth J. D., Phillips R. A., Gallies B. L. pRB controls proliferation, differentiation, and death of skeletal muscle cells and other lineages during embryogenesis. Genes Dev. 10:1996a;3051-3064.
55. Zacksenhaus E., Jiang Z., Phillips R. A., Gallie B. L. Dual mechanisms of repression of E2F1 activity by the retinoblastoma gene product. EMBO J. 15:1996b;5917-5927.
56. kip1. Oncogene. 13:1996;2323-2330.